The effect of metformin on gastric cancer in patients with type 2 diabetes mellitus: an umbrella review
Abstract
Rationale: Gastric cancer (ICD-10-CM Code C16.2) is a multi-factorial disease in its pathology.Diabetes is a chronic, metabolic disease characterized by elevated blood glucose levels.The most common is type 2 diabetes (T2DM), usually in adults.Epidemiological studies reported that T2DM patients have a significant increase in cancer risk and mortality compared to non-diabetic patients.Metformin (a biguanide) is widely used to treat diabetes mellitus and is reported to confer preventive and survival benefits for various malignancies including gastric INPLASY 1 International Platform of Registered Systematic Review and Meta-analysis Protocols INPLASY PROTOCOLThe effect of metformin on gastric cancer in patients with type 2 diabetes mellitus: an umbrella review Htet, NH 1 ; Naing, C 2 ; Tung, WS 3 ; Mak, JW 4 .To cite: Htet et al.The effect of metformin on gastric cancer in patients with type 2 diabetes mellitus: an umbrella review.Inplasy protocol 202130110.
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.